Identification

Name
Temafloxacin
Accession Number
DB01405
Type
Small Molecule
Groups
Withdrawn
Description

Temafloxacin is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths. [Wikipedia]

Structure
Thumb
Synonyms
  • Temafloxacina
  • Temafloxacine
  • Temafloxacinum
Product Ingredients
IngredientUNIICASInChI Key
Temafloxacin hydrochlorideOC5IGJ7J6I105784-61-0QKDHBVNJCZBTMR-UHFFFAOYSA-N
International/Other Brands
Omniflox
Categories
UNII
1WZ12GTT67
CAS number
108319-06-8
Weight
Average: 417.3811
Monoisotopic: 417.130026072
Chemical Formula
C21H18F3N3O3
InChI Key
QKDHBVNJCZBTMR-UHFFFAOYSA-N
InChI
InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)
IUPAC Name
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=O

Pharmacology

Indication

For the treatment of lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections.

Pharmacodynamics

Temafloxacin (marketed by Abbott Laboratories as Omniflox), is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.

Mechanism of action

The bactericidal action of temafloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.

TargetActionsOrganism
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Absorption

Studies in healthy volunteers indicate that the average bioavailability of temafloxacin exceeds 90%, with little intersubject variability.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

Approximately 8 hours in patients with normal renal function.

Clearance
Not Available
Toxicity

Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in about fifty patients during the first four months of its use, leading to three patient deaths

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Temafloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Temafloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Temafloxacin.Experimental, Illicit
AbirateroneThe serum concentration of Temafloxacin can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Temafloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Temafloxacin.Approved, Experimental, Investigational
AcenocoumarolTemafloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temafloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Temafloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Temafloxacin.Approved
AlbiglutideTemafloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Temafloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Temafloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Temafloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Temafloxacin.Experimental
AlogliptinTemafloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Temafloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Temafloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Temafloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Temafloxacin.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Temafloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Temafloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Temafloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Temafloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Temafloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Temafloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Temafloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Temafloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Temafloxacin.Approved
AzithromycinThe metabolism of Temafloxacin can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Temafloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Temafloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Temafloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Temafloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Temafloxacin.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Temafloxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Temafloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Temafloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Temafloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibThe metabolism of Temafloxacin can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Temafloxacin.Approved
BromocriptineTemafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Temafloxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Temafloxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Temafloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Temafloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Temafloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temafloxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Temafloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinTemafloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Temafloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Temafloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Temafloxacin.Approved
ChloroquineChloroquine may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Temafloxacin.Approved
ChlorpropamideTemafloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Temafloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Temafloxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Temafloxacin.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Temafloxacin.Approved, Investigational
CitalopramThe metabolism of Temafloxacin can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Temafloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Temafloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Temafloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Temafloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Temafloxacin.Approved
ClorindioneTemafloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Temafloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Temafloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Temafloxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temafloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Temafloxacin.Experimental
Cyproterone acetateThe serum concentration of Temafloxacin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Temafloxacin.Approved
DeferasiroxThe serum concentration of Temafloxacin can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Temafloxacin.Approved, Investigational
DelamanidTemafloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temafloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Temafloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Temafloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Temafloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Temafloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Temafloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Temafloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Temafloxacin.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
DicoumarolTemafloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Temafloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Temafloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Temafloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Temafloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Temafloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temafloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Temafloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temafloxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Temafloxacin.Approved
DiphenadioneTemafloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Temafloxacin.Approved, Investigational
DisopyramideTemafloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temafloxacin.Approved, Investigational
DosulepinThe metabolism of Temafloxacin can be decreased when combined with Dosulepin.Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Temafloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
DulaglutideTemafloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Temafloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Temafloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Temafloxacin.Investigational
EmpagliflozinTemafloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Temafloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Temafloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Temafloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Temafloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Temafloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Temafloxacin.Experimental
Ethyl biscoumacetateTemafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
ExenatideTemafloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Temafloxacin.Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Temafloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Temafloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Temafloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Temafloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Temafloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Temafloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Temafloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Temafloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Temafloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Temafloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Temafloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Temafloxacin.Approved, Investigational
FluindioneTemafloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Temafloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Temafloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Temafloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Temafloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Temafloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Temafloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Temafloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Temafloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Temafloxacin.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Temafloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Temafloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Temafloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Temafloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Temafloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Temafloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Temafloxacin.Approved, Investigational, Withdrawn
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Temafloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Temafloxacin.Experimental
GliclazideTemafloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Temafloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Temafloxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Temafloxacin.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Temafloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Temafloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Temafloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Temafloxacin.Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Temafloxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Temafloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Temafloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Temafloxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Temafloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Temafloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Temafloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Temafloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
Insulin AspartTemafloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTemafloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTemafloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTemafloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTemafloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTemafloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Temafloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Temafloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Temafloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Temafloxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Temafloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Temafloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Temafloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Temafloxacin.Experimental
Lanthanum carbonateThe serum concentration of Temafloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
LiraglutideTemafloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Temafloxacin.Investigational
LobeglitazoneThe metabolism of Temafloxacin can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Temafloxacin.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Temafloxacin.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Temafloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Temafloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Temafloxacin.Investigational
MecaserminTemafloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Temafloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Temafloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Temafloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Temafloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Temafloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Temafloxacin.Approved
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Temafloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Temafloxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Temafloxacin.Approved, Investigational
MexiletineThe metabolism of Temafloxacin can be decreased when combined with Mexiletine.Approved, Investigational
MidostaurinThe metabolism of Temafloxacin can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneTemafloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTemafloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Temafloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Temafloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Temafloxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Temafloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Temafloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Temafloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Temafloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
NateglinideTemafloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Temafloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
NevirapineThe metabolism of Temafloxacin can be decreased when combined with Nevirapine.Approved
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Temafloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Temafloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Temafloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Temafloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Temafloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Temafloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Temafloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Temafloxacin.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Temafloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Temafloxacin.Vet Approved
OsimertinibThe serum concentration of Temafloxacin can be decreased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Temafloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Temafloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Temafloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temafloxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Temafloxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Temafloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Temafloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Temafloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineTemafloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Temafloxacin.Experimental
PhenindioneTemafloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Temafloxacin.Approved
PhenprocoumonTemafloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Temafloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Temafloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
PioglitazoneTemafloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Temafloxacin.Experimental
PramlintideTemafloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Temafloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Temafloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Temafloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Temafloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Temafloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Temafloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Temafloxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Temafloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Temafloxacin.Experimental
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Temafloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Temafloxacin.Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Temafloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Temafloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Temafloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Temafloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Temafloxacin.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinineTemafloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideTemafloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Temafloxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Temafloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Temafloxacin.Approved, Investigational
RucaparibThe metabolism of Temafloxacin can be decreased when combined with Rucaparib.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Temafloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Temafloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Temafloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Temafloxacin.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Temafloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Temafloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Temafloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Temafloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SimeprevirThe metabolism of Temafloxacin can be decreased when combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Temafloxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Temafloxacin.Investigational
Strontium ranelateThe serum concentration of Temafloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Temafloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineTemafloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleTemafloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Temafloxacin.Approved
SulfisoxazoleTemafloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
SunitinibTemafloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Temafloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Temafloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Temafloxacin.Experimental
Tenofovir disoproxilThe metabolism of Temafloxacin can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may increase the neuroexcitatory activities of Temafloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Temafloxacin.Vet Approved
TeriflunomideThe serum concentration of Temafloxacin can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Terodiline.Experimental
TheophyllineThe metabolism of Theophylline can be decreased when combined with Temafloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Temafloxacin.Approved
TiclopidineThe metabolism of Temafloxacin can be decreased when combined with Ticlopidine.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Temafloxacin.Investigational
TioclomarolTemafloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Temafloxacin.Approved, Withdrawn
TolazamideTemafloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideTemafloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Temafloxacin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temafloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Temafloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Temafloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Temafloxacin.Investigational
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Temafloxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Temafloxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Temafloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Valproic Acid is combined with Temafloxacin.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Temafloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Temafloxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Temafloxacin.Approved
WarfarinTemafloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Temafloxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
ZucapsaicinThe metabolism of Temafloxacin can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02469
PubChem Compound
60021
PubChem Substance
46508032
ChemSpider
54143
ChEBI
77796
ChEMBL
CHEMBL277100
Wikipedia
Temafloxacin
ATC Codes
J01MA05 — Temafloxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-0.20BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP0.94ALOGPS
logP1.08ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)5.6ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.53 m3·mol-1ChemAxon
Polarizability39.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9914
Blood Brain Barrier-0.9863
Caco-2 permeable-0.7526
P-glycoprotein substrateSubstrate0.8741
P-glycoprotein inhibitor INon-inhibitor0.8985
P-glycoprotein inhibitor IINon-inhibitor0.9081
Renal organic cation transporterNon-inhibitor0.7441
CYP450 2C9 substrateNon-substrate0.8128
CYP450 2D6 substrateNon-substrate0.9072
CYP450 3A4 substrateNon-substrate0.7309
CYP450 1A2 substrateNon-inhibitor0.8664
CYP450 2C9 inhibitorNon-inhibitor0.9304
CYP450 2D6 inhibitorNon-inhibitor0.9413
CYP450 2C19 inhibitorNon-inhibitor0.9048
CYP450 3A4 inhibitorNon-inhibitor0.8858
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6993
Ames testAMES toxic0.9067
CarcinogenicityNon-carcinogens0.8318
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0973 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8332
hERG inhibition (predictor II)Non-inhibitor0.7289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Phenylquinolines
Direct Parent
Phenylquinolines
Alternative Parents
Quinoline carboxylic acids / Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Fluorobenzenes
show 13 more
Substituents
Phenylquinoline / Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, tertiary amino compound, N-arylpiperazine, monocarboxylic acid, secondary amino compound, amino acid, quinolone antibiotic, quinolone (CHEBI:77796)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Frank KE, Devasthale PV, Gentry EJ, Ravikumar VT, Keschavarz-Shokri A, Mitscher LA, Nilius A, Shen LL, Shawar R, Baker WR: A simple, inexpensive apparatus for performance of preparative scale solution phase multiple parallel synthesis of drug analogs. II. Biological evaluation of a retrospective library of quinolone antiinfective agents. Comb Chem High Throughput Screen. 1998 Jun;1(2):89-99. [PubMed:10500768]
  4. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Yamaguchi T, Mitsuhashi S: Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Dec;35(12):2562-7. [PubMed:1667255]
  5. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Mitsuhashi S: Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Jun;35(6):1053-9. [PubMed:1656852]
  6. Appelbaum PC: Mechanisms and frequency of resistance to temafloxacin. Am J Med. 1991 Dec 30;91(6A):27S-30S. [PubMed:1662892]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Yamaguchi T, Mitsuhashi S: Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Dec;35(12):2562-7. [PubMed:1667255]
  4. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Mitsuhashi S: Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Jun;35(6):1053-9. [PubMed:1656852]
  5. Appelbaum PC: Mechanisms and frequency of resistance to temafloxacin. Am J Med. 1991 Dec 30;91(6A):27S-30S. [PubMed:1662892]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on July 13, 2007 14:27 / Updated on August 02, 2018 07:44